Mereo BioPharma Group plc
MREO
NASDAQ·Healthcare·Biotechnology·Mkt cap $39.9M
$0.25
▼ -8.16%
P/E
-2.72
Mkt Cap
$39.9M
52-Wk Range
$0.20–$2.37
52-Week Range
$0.20 - $2.37
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 86.0% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
No bull reasons captured for this rating yet.
Bear Case
1 risk
- Low volatility (beta 0.3).
Growth
Stable outlook
Value
Deep value opportunity - significant discount to sector peers
Momentum
Weak
-18.0% over 3m
Quality
Loss-making
Below average quality
Dividend
None
No dividend
Smart-money signal
Who's buying MREO right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 9, 2026
AUG 11, 2026
Reported EPS of -$0.01 vs -$0.01 consensus (0.0% surprise).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
0.0%
Revenue trend · last 2Q
—
—
Q1 26
Q2 26
$0
$0
Margins · last 2Q
No margin history available.
Wall Street consensus
2 analysts · 50% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
50%
Hold
50%
Sell
0%
Median Price Target
—
Latest: BTIG · May 12, 2026
vs Industry
How MREO stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.